MBX Biosciences, Inc.

NasdaqGS:MBX Stock Report

Market Cap: US$618.2m

MBX Biosciences Future Growth

Future criteria checks 0/6

MBX Biosciences's earnings are forecast to decline at 25.7% per annum. EPS is expected to grow by 12.2% per annum.

Key information

-25.7%

Earnings growth rate

12.2%

EPS growth rate

Pharmaceuticals earnings growth23.7%
Revenue growth raten/a
Future return on equity-29.9%
Analyst coverage

Low

Last updated08 Nov 2024

Recent future growth updates

No updates

Recent updates

MBX Biosciences: Decent Potential For Lead Indication, But Need More Data

Nov 14

Earnings and Revenue Growth Forecasts

NasdaqGS:MBX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026N/A-105N/A-1103
12/31/2025N/A-80-80-744
12/31/2024N/A-66-62-584
9/30/2024N/A-55-51-50N/A
6/30/2024N/A-47-44-43N/A
3/31/2024N/A-39-37-37N/A
12/31/2023N/A-33-32-32N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MBX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MBX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MBX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if MBX's revenue is forecast to grow faster than the US market.

High Growth Revenue: MBX is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MBX is forecast to be unprofitable in 3 years.


Discover growth companies